Granted Patent
B2
US 12,735,471 · App. 18/121,101 · Granted Sep 15, 2026
Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof
Inventors:
Yupo Ma (Stony Brook, NY); Kevin Pinz (Stony Brook, NY); Xun Jiang (Stony Brook, NY); Masayuki Wada (Stony Brook, NY); Kevin Chen (Stony Brook, NY)
Assignee:
iCell Gene Therapeutics Inc.
C07K14/7051A61K39/39A61K40/11A61K40/31A61K40/4224A61K48/00A61K48/005C07K14/70521C07K14/70578C07K16/2806C07K16/2809C07K16/2812C07K16/2896C12N5/0636C12N5/0646C12N9/224C12N15/1138A61K38/00A61K2039/505A61K2239/48C07K2317/622C07K2319/00C07K2319/03C07K2319/33C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides chimeric anti-gen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the poly-nucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.
Claims (3)
1 . A method of treating T-cell acute lymphoblastic leukemia (T-ALL) in a patient in need thereof, wherein said method comprises administering to said patient an engineered cell expressing a polypeptide comprising a chimeric antigen receptor polypeptide (CAR), where the CAR comprises a signal peptide, an antigen recognition domain, a hinge region, a transmembrane domain, at least one co-stimulatory domain, and a signaling domain and wherein the antigen recognition domain is selective for CD 7 .
2 . The method according to claim 1 , wherein the engineered cell is a T or NK cell.
3 . The method according to claim 1 , wherein the engineered cell is administered in conjunction with radiation therapy, hormone therapy, chemotherapy, checkpoint inhibitor, immunotherapy or a combination thereof.
Assignments (2)
MERGER AND CHANGE OF NAME
Recorded Mar 25, 2025
From: ICELL GENE THERAPEUTICS LLC; ICELL GENE THERAPEUTICS INC.
To: ICELL GENE THERAPEUTICS INC.
Reel/Frame 070614/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 14, 2023
From: MA, YUPO; PINZ, KEVIN; JIANG, XUN; WADA, MASAYUKI; CHEN, KEVIN
To: ICELL GENE THERAPEUTICS LLC
Reel/Frame 062972/0401 →
Continuity (4)
Provisional Application
62121842
· Feb 27, 2015
References Cited (162)
US 5350674A
· Boenisch et al.
· 1994
[cited by applicant]
US 6326193B1
· Liu et al.
· 2001
[cited by applicant]
US 6762030B2
· Lyman
· 2004
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 9328156B2
· June et al.
· 2016
[cited by applicant]
US 20020009449A1
· Wallner et al.
· 2002
[cited by applicant]
US 20030147865A1
· Salomon et al.
· 2003
[cited by applicant]
US 20040265315A1
· Dingivan et al.
· 2004
[cited by applicant]
US 20050277587A1
· Chen et al.
· 2005
[cited by applicant]
US 20080254027A1
· Bernett et al.
· 2008
[cited by applicant]
US 20080254512A1
· Capon
· 2008
[cited by applicant]
US 20080299042A1
· Bechtel et al.
· 2008
[cited by applicant]
US 20120058082A1
· Kaplan et al.
· 2012
[cited by applicant]
US 20130058936A1
· Bruenker et al.
· 2013
[cited by applicant]
US 20160207989A1
· Short
· 2016
[cited by applicant]
CA 2904265A1
· 2014
[cited by examiner]
CN 103492406A
· 2014
[cited by applicant]
CN 104004092B
· 2014
[cited by applicant]
CN 106029875A
· 2016
[cited by applicant]
CN 107075483A
· 2017
[cited by applicant]
CN 107249602A
· 2017
[cited by applicant]
CN 107709548A
· 2018
[cited by applicant]
WO 0129058A1
· 2001
[cited by applicant]
WO 0196584A2
· 2001
[cited by applicant]
WO 02060480A1
· 2002
[cited by applicant]
WO 2008121160A2
· 2008
[cited by applicant]
WO 2009091826A1
· 2009
[cited by applicant]
WO 2009112502A1
· 2009
[cited by applicant]
WO 2012079000A1
· 2012
[cited by applicant]
WO WO2013126712A1
· 2013
[cited by applicant]
WO 2013169691A1
· 2013
[cited by applicant]
WO WO2014055668A1
· 2014
[cited by applicant]
WO 2014100139A1
· 2014
[cited by applicant]
WO WO2014100385A1
· 2014
[cited by applicant]
WO 2014124143A1
· 2014
[cited by applicant]
WO WO2014127261A1
· 2014
[cited by applicant]
WO WO2014184143A1
· 2014
[cited by applicant]
WO WO2015075469A1
· 2015
[cited by applicant]
WO WO2015075470A1
· 2015
[cited by applicant]
WO 2015121454A1
· 2015
[cited by applicant]
WO WO2015120180A1
· 2015
[cited by applicant]
WO WO2015157399A9
· 2015
[cited by applicant]
WO WO2015168613A2
· 2015
[cited by applicant]
WO WO2015172339A1
· 2015
[cited by applicant]
WO 2016011210A2
· 2016
[cited by applicant]
WO WO2016014553A1
· 2016
[cited by applicant]
WO WO2016102965A1
· 2016
[cited by applicant]
WO 2016126213A1
· 2016
[cited by applicant]
WO 2016138491A1
· 2016
[cited by applicant]
WO 2016172606A1
· 2016
[cited by applicant]
WO 2016210293A1
· 2016
[cited by applicant]
WO WO2017068361A1
· 2017
[cited by applicant]
WO WO2015075468A1
· 2018
[cited by applicant]
Janeway, C. A. Jr. et al., Immunobiology: The Immune System in Health and Disease. Chapter 3: Structure of the Antibody Molecule and Immunoglobulin Genes. 3rd Edition, 1997 Garland Publishing Inc., pp. 3:1-3:11 (Year: 1…
[cited by examiner]
Edwards, B. M. et al. The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS. J Mol Biol 2003; 334:103-118. (Year: 2003).
[cited by examiner]
Sadelain et al. “The Basic Principles of Chimeric Antigen Receptor Design” Cancer Discov. 2013;3(4):388â398 (Year: 2013).
[cited by examiner]
Bierer et al., Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology, Curr. Opin. Immun., vol. 5, 1993, pp. 763-773 (abst).
[cited by applicant]
Brentjens, Renier J., et al. “Eradication of Systemic B-Cell Tumors by Genetically Targeted Human T Lymphocytes Co-Stimulated by CD80 and Interleukin-15,” Nature Medicine. vol. 9, No. 3, pp. 279-286 (2003).
[cited by applicant]
C. Imai, “Chimeric receptors with 4-1 BB singnaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia,” Leukemia 2001; vol. 18.
[cited by applicant]
Caruana et al., “From Monoclonal Antibodies to Chimeric Antigen Receptoers for the Treatment of Human Malignancies,” Semin. Oncol., Oct. 2014; 41(5): 661-666.
[cited by applicant]
Cheadle et al: “Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells”, Gene Therapy, vol. 19, No. 11, Dec. 1, 2011 (Dec. 1, 2011), pp. 1114-1120, X…
[cited by applicant]
Chen, Li Juan et al., “T Analysis of immunophenotype of acute lymphoblastic leukemia,” Chinese Journal of Experimental Hematology, 2007, 15(4).
[cited by applicant]
Feng et al., “Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells,” Stem Cell Reviews and Reports, pub online https://doi.org/10.1007/s12015-0200-10092-9, Jan. 1, 2021.
[cited by applicant]
Geldres et al., “Chimeric antigen receptor-redirected T cells return to the bench,” Seminars in Immunology, 2016, 28 (1).
[cited by applicant]
Torkai, Hiroki et al., A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 2012, vol. 119, No…
[cited by applicant]
Ui-Tei et al., “Sensitive assay of RNA interference in
[cited by applicant]
Wang et al: “Structure of a Heterophilic Adhesion Complex between the Human CD2 and CD58 (LFA-3) Counterreceptors”, Cell, vol. 97, No. 6, Jun. 11, 1999 (Jun. 11, 1999), Amsterdam, NL, pp. 791-803, XP055627194, ISSN: 009…
[cited by applicant]
Grupp et al., “Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia,” New England Journal of Medicine, vol. 368, No. 16, pp. 1509-1518 (Apr. 18, 2013).
[cited by applicant]
Rowley et al., “Expression of IL-15RA or an IL-15/IL-15RA Fusion on CD8+ T Cells Modifies Adoptively Transferred T-Cell Function in Cis,” Eur J Immunol, vol. 39, No. 2, pp. 491-506 (Jan. 29, 2009).
[cited by applicant]
John et al., “Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells,” Clin Cancer Res, Oct. 15, 2013, vol. 19, No. 20, pp. 5636-5646.
[cited by applicant]
Penney et al., “Greater Frequency of CD5-Negative CD8(+) T Cells Against Human Immunodeficiency Virus Type 1 than other Viruses is Consistent with Adaptation to Antigenic Variation,” AIDS Res Ther, Sep. 15, 2014, vol. 1…
[cited by applicant]
Maus et al., “Antibody-Modified T Cells: CARs take the Front Seat for Hematologic Malignancies,” Blood, Apr. 24, 2014, vol. 123, No. 17, pp. 2625-2635.
[cited by applicant]
D'Amore et al., “Phase II Trial of Zanolimumab (HuMax-CD4) in Relapsed or Refractory Non-Cutaneous Peripheral T Cell Lymphoma,” Br J Haematol 2010, 150: 565-573.
[cited by applicant]
Shenghui et al., “Elevated Frequencies of CD4+CD25+CD127lo Regulatory T Cells is Associated to Poor Prognosis in Patients with Zcute Myeloid Leukemia,” Int. J. Cancer, vol. 129, pp. 1373-1381 (2011).
[cited by applicant]
Ehninger et al., “Distribution and Levels of Cell Surface Expression of CD33 and CD123 in Acute Myeloid Leukemia,” Blood Cancer Journal 2014, vol. 4, pp. 1-10.
[cited by applicant]
Liu et al., “Tumor_Associated Macrophages Via Up-Regulation of PD1 Ligands Protect Neuroblastoma from Immunotherapy With NKT Cells Expressing GD2-Specific Chimeric Antigen Receptor,” Molecular Therapy, vol. 23, Supp. 1,…
[cited by applicant]
Rouce et al., “Equal Opportunity CAR T Cells,” Blood 2017, 129:3275-3277.
[cited by applicant]
Lai et al., “The Roles of CD4+ T Cells in Tumor Immunity,” ISRN Immunology, vol. 2011, Article ID 497397, 6 pages, doi:10.5402/2011/497397.
[cited by applicant]
Kebriaei et al., “Phase I Trials Using Sleeping Beauty to Generate CD19-Specific CAR T Cells,” The Journal of Clinical Investigation, vol. 126, No. 9, Sep. 2016, pp. 3363-3376 and Supplemental Tables.
[cited by applicant]
Leavitt et al ., “Concordant Modulation of Neutralization Resistance and High Infectivity of the Primary Human Immunodeficiency Virus Type 1 MN Strain and Definition of a Potential gp41 Binding Site in gp120”, Journal o…
[cited by applicant]
Schreiber et al., “Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion”; pp. 1565-1570.
[cited by applicant]
Marzo et al, “Fully Functional Memory CDS T Cells in the Absence of CD4 T Cells”, J Immunol 2004; 173:969-975.
[cited by applicant]
Moeller et al., “Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CDS+ T Cells”, Cancer Res 2007; 67: (23). December 1 pp. 11428-11437.
[cited by applicant]
Lai, et al., International Scholarly Research Network 2011; pp. 1-6.
[cited by applicant]
Moeller et al, “Adoptive Transfer of Gene-Engineered CD4 Helper T Cells Induces Potent Primary and Secondary Tumor Rejection,” Blood, Nov. 1, 2005 vol. 106, No. 9; pp. 2995-3003.
[cited by applicant]
Gibson, et al., “Risk of Non-Hodgkin Lymphoma Subtypes in HIV-Infected People During the HAART Era: A Population-Based Study,” AIDS. Sep. 24, 2014; 28(15): 2313-2318.
[cited by applicant]
Liu, et al., Molecular Therapy vol. 23, Supplement 1, May 2015 Abstract 512.
[cited by applicant]
Beard, et al., “Multiple Chimeric Antigen Receptors Successfully Target Chondroitin Sulfate Proteoglycan 4 in Several Different Cancer Histologies and Cancer Stem Cells,” Journal for ImmunoTherapy of Cancer 2014; 2(25),…
[cited by applicant]
Imboden, et al., “Stimulation of CDS Enhances Signal Transduction by the T Cell Antigen Receptor,” J. Clin. Invest. 1990; 85:130-134.
[cited by applicant]
Rabinowich, et al., “Signaling Via CD7 Molecules on Human NK Cells. Induction of Tyrosine Phosphorylation and Beta 1 Integrin-Mediated Adhesion to Fibronectin,” J. Immunol. 1994; 153:3504-3513.
[cited by applicant]
Inoue, et al., “Mechanisms of NK Cell Activation Stimulated by CD2; Granzyme B is Released by CD2 Crosslinking-Stimulation on NK92 Cell,” J Osaka Dent Univ (Oct. 2012) 46(2): 229-235.
[cited by applicant]
Mcnerney, et al., “The CD2 Family of Natural Killer Cell Receptors,” Curr Top Microbiol Immuhnol 2006; 298:91-120.
[cited by applicant]
Rabinowich et al., “Expression and Function of CD7 Molecule on Human Natural Killer Cells,” J Immunol 1994; 152:517-526.
[cited by applicant]
Liu, et al., “Critical Role of CD2 Co-Stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2CDeficient Humans,” Cell Reports 2016; 15, 1088-1099.
[cited by applicant]
Brown, Jennifer R. et al., “Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward”, American Society of Clinical Oncology, 2014 Asco Educational Book.
[cited by applicant]
Sommermeyer, Daniel, et al., “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo”, Leukemia, Feb. 2016; 30(2): 492-500.
[cited by applicant]
Curran, Kevin, et al., “Chimeric Antigen Receptors for T Cell Immunotherapy: Current Understanding and Future Directions.” The Journal of Gene Medicine, 14.(6), pp. 405-415, Jun. 2012.
[cited by applicant]
Dotti, G., et al., “Design and Development of Therapies Using Chimeric Antigen Receptor-Expressing T Cells.” Immunological Reviews, 257, No. 1: pp. 107-126, Jan. 2014.
[cited by applicant]
Shirasu, N., et al., “Functional Design of Chimeric T-Cell Antigen Receptors for Adoptive Immunotherapy of Cancer: Architecture and Outcomes”, Anticancer Research, 32(6), pp. 2377-2384, 2012.
[cited by applicant]
Bridgeman, J.S., et al., “CD 3ζ-Based Chimeric Antigen Receptors Mediate T Cell Activation Via Cis-and Trans-Signalling Mechanisms: Implications for Optimization of Receptor Structure for Adoptive Cell Therapy”, Clinica…
[cited by applicant]
Kaiser, A.D., et al., “Towards a Commercial Process for the Manufacture of Genetically Modified T Cells for Therapy”, Cancer Gene Therapy, 22(2), pp. 72-78, Jan. 2015.
[cited by applicant]
Sentman, C.L., “Challenges of Creating Effective CARs for Cancer Therapy”, Immunotherapy, 5(8), pp. 783-785, 2013.
[cited by applicant]
Abate-Daga, et al., “CAR Models: Next-Generation CAR Modifications for Enhanced T-Cell Function,” Molecular Therapy—Oncolytics 3 (2016): 16014.
[cited by applicant]
EPO Intention to Grant of Nov. 22, 2021.
[cited by applicant]
Aandahl, E. et al., “Expansion of CD7low and CD7negative CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment”—Blood, Dec. 1, 2004—vol. 104, No. 12, p…
[cited by applicant]
Lazarovits, A. et al.—Modulation of CD7 is associated with inhibition of T cell proliferation in response to tetanus toxoid and phytohemagglutinin—https://pubmed.ncbi.nlm.nih.gov/2469235/.
[cited by applicant]
Costantinides, Y. et al.—Inhibition of lymphocyte proliferation by a monoclonal antibody (RFT2) against CD7—Clin. exp. Immunol. (1991) 85, 164-167.
[cited by applicant]
Lazarovits, A. et al.—A monoclonal antibody, 7G5 (CD7), induces modulation of Tp40 and inhibits proliferation in the allogeneic and autologous mixed lymphocyte reactions—https://pubmed.ncbi.nlm.nih.gov/2462292/.
[cited by applicant]
Amlot, P. et al.—Chapter 18 CD7 Monoclonal Antibodies—Therapeutic Monoclonal Antibodies (1990)—pp. 287-288.
[cited by applicant]
European Office Action of Apr. 7, 2021.
[cited by applicant]
Communication and Supplemental Search Report of Oct. 10, 2018.
[cited by applicant]
European Response of Apr. 21, 2021.
[cited by applicant]
Png, Yi Tian, et al. “Blockade of CD7 Expression in T Cells for Effective Chimeric Antigen Receptor Targeting of T-Cell Malignancies,” Blood Advances, vol. 1, No. 25, pp. 2348-2360 (2017).
[cited by applicant]
Böldicke, Thomas, “Blocking Translocation of Cell Surface Molecules from the ER to the Cell Surface by Intracellular Antibodies Targeted to the ER,” Journal of Cellular and Molecular Medicine, vol. 11, No. 1, pp. 54-70 …
[cited by applicant]
Arafat, Waleed, et al. “Antineoplastic Effect of Anti-ErbB-2 Intrabody is not Correlated with scFv Affinity for its Target,” Cancer Gene Therapy, vol. 7, No. 9, pp. 1250-1256 (2000).
[cited by applicant]
Notice of Opposition filed in the European Patent Office corresponding to Application No. 16756524.1-1111/3261651, dated Feb. 9, 2023.
[cited by applicant]
Morris, John C., et al. ,“Antibody-based therapy of leukaemia” Expert Rev Mol Med; 11: e29, Jun. 2020.
[cited by applicant]
Lewis, et al., “The immunophenotype of pre-TALL/LBL revisited”, Experimental and Molecular Pathology 81 (2006), pp. 162-165.
[cited by applicant]
Glienke, Wolfgang, et al., “Advantages and applications of CAR-expressing natural killer cells”, Frontiers in Pharmacology vol. 6, Article 21, Feb. 2015.
[cited by applicant]
Pinz, Kevin, et al., “Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells”, Leukemia accepted article preview 3, Nov. 2015; doi: 10.1038/leu.2015.311.
[cited by applicant]
Vinante, F., et al., “The CD4 molecule belongs to the phenotypic repertoire of most cases of acute myeloid leukemia”, Leukemia, 1992, 6(12): 1257-1262. (Abstract).
[cited by applicant]
Mamonkin, Maksim, et al., “A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies”, Blood, Aug. 20, 2015, 126(8): 983-992.
[cited by applicant]
Jena, Bipulendu, et al., “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor”, Blood, Aug. 19, 2010, 1035-1044, vol. 116, No. 7.
[cited by applicant]
Sadelain, Michel, et al., “The Basic Principles of Chimeric Antigen Receptor Design”, Cancer Discov. Apr. 2013; 3(4):388-98.
[cited by applicant]
Kapp, Katja, et al., “Post-Targeting Functions of Signal Peptides”, In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013, pp. 1-16.
[cited by applicant]
Miwa, H., et al., “Leukemia”, Jan. 1998; 12(1):44-51.
[cited by applicant]
Choi, Mira, et al., “A Case of Primary Cutaneous CD4 Postive Small/medium T Cell Lymphoma”, Ann Dermatol, vol. 23, No. 1, 2011, pp. 76-80.
[cited by applicant]
Hishima, Tsunekazu, et al., “CD5 Expression in Thymic Carcinoma”, American Journal of Pathology, vol. 145, No. 2, Aug. 1994; pp. 268-275.
[cited by applicant]
Hussong, Jerry W., et al., “Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms”, College of American Pathologists. Version: NonHodgkin 3.2.0.1, Oct. 2013.
[cited by applicant]
Li, Shiyong, et al., “Flow Cytometry in the Differential Diagnosis of Lymphocyte-Rich Thymoma From Precursor T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma”, Am J Clin Pathol, 2004;121 :268-274.
[cited by applicant]
Rezvani, Katayoun, et al., “The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer”, Front Immunol., Nov. 17, 2015; 6:578; pp. 1-13.
[cited by applicant]
Frankel, Frankel E., et al., “Therapy of Patients with T-cell Lymphomas and Leukemias Using an Anti-CD7 Monoclonal Antibody-Rich a Chain Immunotoxin”, Leukemia & Lymphoma, vol. 26, 1997, pp. 287-298.
[cited by applicant]
Posey, Avery, D., et al., “Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia”, Blood, vol. 124, 2014.
[cited by applicant]
Lemaistre, C.F., “Phase I Trial of H65-RTA Immunoconjugate in Patients With Cutaneous T-cell Lymphoma”, Blood, vol. 78, No. 5, Sep. 1, 1991, pp. 1173-1182.
[cited by applicant]
Chen, Li-Juan, et al., “Immunophenotyping Characteristics of T-cell Acute Lymphblastic Leukemia”, Journal of Experimental Hematology 2007; 15(4); 692-695.
[cited by applicant]
Zhang, et al., “CD2, CD3, CD5, and CD7 expression in unspecified peripherial T cell lymphoma and reactive lymphoid hyperplasia”, J Diag Pathol., Apr. 2007, vol. 14, No. 2.
[cited by applicant]
“T-cell antigen CD7 precursor [
[cited by applicant]
“T-cell surface antigen CD2 precursor [
[cited by applicant]
“T-cell surface glycoprotein CD3 epsilon chain precursor [
[cited by applicant]
“T-cell surface gyloprotein CD5 precursor [
[cited by applicant]